3151 related articles for article (PubMed ID: 7646923)
21. Heterogenous S-100B protein expression patterns in malignant melanoma and association with serum protein levels.
Bánfalvi T; Udvarhelyi N; Orosz Z; Gergye M; Gilde K; Tímár J
Oncology; 2003; 64(4):374-9. PubMed ID: 12759535
[TBL] [Abstract][Full Text] [Related]
22. Temporal profile and clinical significance of serum neuron-specific enolase and S100 in ischemic and hemorrhagic stroke.
Brea D; Sobrino T; Blanco M; Cristobo I; Rodríguez-González R; Rodríguez-Yañez M; Moldes O; Agulla J; Leira R; Castillo J
Clin Chem Lab Med; 2009; 47(12):1513-8. PubMed ID: 19863297
[TBL] [Abstract][Full Text] [Related]
23. Significance of serum protein S100 levels in screening for melanoma metastasis: does protein S100 enable early detection of melanoma recurrence?
Schlagenhauff B; Schittek B; Ellwanger U; Stroebel W; Blum A; Schwarz M; Rassner G; Garbe C
Melanoma Res; 2000 Oct; 10(5):451-9. PubMed ID: 11095406
[TBL] [Abstract][Full Text] [Related]
24. Detection of melanoma relapse: first comparative analysis on imaging techniques versus S100 protein.
Beyeler M; Waldispuhl S; Strobel K; Joller-Jemelka HI; Burg G; Dummer R
Dermatology; 2006; 213(3):187-91. PubMed ID: 17033166
[TBL] [Abstract][Full Text] [Related]
25. Multicenter evaluation of the analytical and clinical performance of the Elecsys S100 immunoassay in patients with malignant melanoma.
Alber B; Hein R; Garbe C; Caroli U; Luppa PB
Clin Chem Lab Med; 2005; 43(5):557-63. PubMed ID: 15899680
[TBL] [Abstract][Full Text] [Related]
26. [Serum S100B protein and stage of cutaneous melanoma: a prospective study].
Brouard M; Quillien V; Ollivier I; Lesimple T; Adamski H; Chevrant-Breton J
Ann Dermatol Venereol; 2000 Jan; 127(1):56-9. PubMed ID: 10717564
[TBL] [Abstract][Full Text] [Related]
27. [Protein S100 beta and Melanoma Inhibitory Activity (MIA): a prospective study of their clinical value for the early detection of metastasis in malignant melanoma].
Loppin M; Quillien V; Adamski H; Ollivier I; Garlantézec R; Chevrant-Breton J
Ann Dermatol Venereol; 2007; 134(6-7):535-40. PubMed ID: 17657179
[TBL] [Abstract][Full Text] [Related]
28. S100 serum level: a tumour marker for metastatic melanoma.
Bottoni U; Izzo P; Richetta A; Mannooranparampil TJ; Devirgiliis V; Del Giudice M; Reale MG; Frati L; Calvieri S
Melanoma Res; 2003 Aug; 13(4):427-9. PubMed ID: 12883371
[No Abstract] [Full Text] [Related]
29. Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma.
Egberts F; Kotthoff EM; Gerdes S; Egberts JH; Weichenthal M; Hauschild A
Eur J Cancer; 2012 Mar; 48(5):695-702. PubMed ID: 21917447
[TBL] [Abstract][Full Text] [Related]
30. Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma.
Hamberg AP; Korse CM; Bonfrer JM; de Gast GC
Melanoma Res; 2003 Feb; 13(1):45-9. PubMed ID: 12569284
[TBL] [Abstract][Full Text] [Related]
31. Elevated serum levels of S100 and survival in metastatic malignant melanoma.
Buer J; Probst M; Franzke A; Duensing S; Haindl J; Volkenandt M; Wittke F; Hoffmann R; Ganser A; Atzpodien J
Br J Cancer; 1997; 75(9):1373-6. PubMed ID: 9155061
[TBL] [Abstract][Full Text] [Related]
32. Prognostic Value of Early S100 Calcium Binding Protein B and Neuron-Specific Enolase in Patients with Poor-Grade Aneurysmal Subarachnoid Hemorrhage: A Pilot Study.
Abboud T; Mende KC; Jung R; Czorlich P; Vettorazzi E; Priefler M; Kluge S; Westphal M; Regelsberger J
World Neurosurg; 2017 Dec; 108():669-675. PubMed ID: 28943424
[TBL] [Abstract][Full Text] [Related]
33. Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy.
Hauschild A; Engel G; Brenner W; Gläser R; Mönig H; Henze E; Christophers E
Br J Dermatol; 1999 Jun; 140(6):1065-71. PubMed ID: 10354072
[TBL] [Abstract][Full Text] [Related]
34. Comparative study on the clinical use of protein S-100B and MIA (melanoma inhibitory activity) in melanoma patients.
Schmitz C; Brenner W; Henze E; Christophers E; Hauschild A
Anticancer Res; 2000; 20(6D):5059-63. PubMed ID: 11326668
[TBL] [Abstract][Full Text] [Related]
35. Serum protein s100beta in patients with malignant melanoma detected by an immunoluminometric assay.
Wollina U; Karte K; Hipler UC; Knöll B; Kirsch K; Herold C
J Cancer Res Clin Oncol; 2000 Feb; 126(2):107-10. PubMed ID: 10664251
[TBL] [Abstract][Full Text] [Related]
36. Baseline staging of melanoma with unknown primary site: the value of serum s100 protein and positron emission tomography.
Oberholzer PA; Urosevic M; Steinert HC; Dummer R
Dermatology; 2008; 217(4):351-5. PubMed ID: 18799883
[TBL] [Abstract][Full Text] [Related]
37. Neurone specific enolase and S100 protein as possible prognostic indicators in melanoma.
Rode J; Dhillon AP
Histopathology; 1984 Nov; 8(6):1041-52. PubMed ID: 6526386
[TBL] [Abstract][Full Text] [Related]
38. Neuron specific enolase (NSE) in serum of patients with malignant melanoma.
Wibe E; Paus E; Aamdal S
Cancer Lett; 1990 Jun; 52(1):29-31. PubMed ID: 2354416
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of somatosensory evoked potentials, neuron-specific enolase, and S100 for short-term outcome in ischemic stroke.
Haupt WF; Chopan G; Sobesky J; Liu WC; Dohmen C
J Neurophysiol; 2016 Mar; 115(3):1273-8. PubMed ID: 26745251
[TBL] [Abstract][Full Text] [Related]
40. Comparison of serial S-100 and NSE serum measurements after severe head injury.
Woertgen C; Rothoerl RD; Holzschuh M; Metz C; Brawanski A
Acta Neurochir (Wien); 1997; 139(12):1161-4; discussion 1165. PubMed ID: 9479423
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
